EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Metagenomi, Inc. (MGX) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Metagenomi, Inc. $2.73, price $1.13, upside +141.6%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US59102M1045

MI Metagenomi, Inc. logo Thin data Sep 24, 2026

Metagenomi, Inc.

MGX · US

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value $2.73 · Strongly undervalued (+142%)
!Quality 38/100
!Expensive Growth (revenue 3y +13.6 %/yr)
!negative free cash flow
!Mixed vs. peers (3/7)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch Metagenomi, Inc. Common Stock for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$15.00 $1.10 Fair Value $2.73 Feb 2024 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

31‑month range $1.10 – $15.00 · fair‑value band $1.80 – $3.41 · the $1.13 price screens below the $2.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Metagenomi, Inc. Common Stock in your weekly email

Every Wednesday you see whether Metagenomi, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia.

Show more

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.

Stock analysis

Metagenomi, Inc. Common Stock (MGX) currently trades at $1.13, while our model-based Fair Value estimate is $2.73, implying the stock looks roughly 58.6% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $1.80 (bear) to $3.41 (bull), the price of $1.13 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Metagenomi, Inc. Common Stock reported revenue of $25.2M in FY2025 versus $243K in FY2021, a compound +219.1%/yr. Reported net income was −$87.9M in FY2025.

Key figures

Market cap $42.6M · P/S ratio 3.20 · EPS (TTM) $−2.46 · Return on equity −60.6% · Return on assets (EBIT) −24.0% · Operating margin 11,196% · Revenue (TTM) $13.6M · Revenue growth (YoY) −69.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 66% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 142%, MGX screens cheaper than that median.

Fair Value models

Bear $1.80 Fair Value $2.73 Bull $3.41
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $2.10 $2.81 $4.20 51
All 1 models by family
Asset-Based
NCAV (Graham) $2.10 $2.81 $4.20 51

Open the full fair value analysis →

Notify me when MGX reaches fair value

Put MGX on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 38/100

Of which business quality 38 · Market factors (momentum, volatility) 22

Profitability 3
Margins and returns on capital today
Quality Growth 5
Are margins and returns improving?
Cashflow 11
Earnings quality: real cash, not paper profit
Fin. Strength 66
Balance sheet, leverage, solvency risk
Investment 99
Disciplined investing over empire-building
Low Volatility 43
Calm price path (market factor)
Momentum 19
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)
Net Issuance 75
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 37/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−51.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−9,854.7% (2021) → −380.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch MGX, get fair value alerts →

Compare Metagenomi, Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 39 · Below median
Fair Value upside +142% · Top 25%
Profitability
Return on assets −28% · Below median
Growth and dividend
Revenue growth −70% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.27× · Cheapest 25%
P/S (TTM) 3.14× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $516.34 $567.97 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Metagenomi, Inc. Common Stock · Fair Value
$2.73 +59%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Metagenomi, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/MGX

Frequently asked questions

Is Metagenomi, Inc. (MGX) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $2.73 versus a price of $1.13, about +142% upside (undervalued).
What is the fair value of MGX?
Our model-based fair value for Metagenomi, Inc. Common Stock is $2.73 (as of Sep 24, 2026), built from audited fundamentals. The current price: $1.13.
What is the quality score of MGX?
Metagenomi, Inc. Common Stock has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Metagenomi, Inc. (MGX)?
Our model-based price target is the fair value of $2.73 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $1.80, optimistic scenario $3.41. It is a calculation from audited fundamentals, not an analyst target.
What is the Metagenomi, Inc. Common Stock stock forecast for 2026?
Our models put fair value at $2.73, about +142% upside versus a price of $1.13 (undervalued). Cautious scenario $1.80, optimistic scenario $3.41. The calculation is refreshed regularly with new filings.
What is the revenue of Metagenomi, Inc. (MGX)?
Metagenomi, Inc. Common Stock reported trailing-twelve-month revenue of about $13.6M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Metagenomi, Inc. (MGX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Metagenomi, Inc. Common Stock it is $2.73 per share (as of Sep 24, 2026), against a price of $1.13. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Metagenomi, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Sep 24, 2026, MGX trades below its calculated fair value: price $1.13, fair value $2.73, a gap of about +142% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MGX?
No. The price is what the market pays today ($1.13); the fair value is what the company's own numbers justify ($2.73). For Metagenomi, Inc. Common Stock the two are $1.60 per share apart. That gap is exactly why we show both numbers side by side.
How much is Metagenomi, Inc. Common Stock worth?
The market values Metagenomi, Inc. Common Stock at about $42.6M (market capitalisation, as of Sep 24, 2026). Per share that is $1.13; our models calculate a fair value of $2.73 per share.
What do the bullish and bearish scenarios say about MGX?
Our models span a range for Metagenomi, Inc. Common Stock: cautious scenario $1.80, base $2.73, optimistic $3.41 per share (as of Sep 24, 2026, price $1.13). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Metagenomi, Inc. (MGX)?
Balance-sheet figures for Metagenomi, Inc. Common Stock (as of Sep 24, 2026): return on equity −60.6%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is MGX from its 52-week high?
Metagenomi, Inc. Common Stock trades at $1.13, about 66% below its 52-week high of $3.35 and 3% above the low of $1.10 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $2.73 is for.
Which stocks are comparable to Metagenomi, Inc. Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Metagenomi, Inc. Common Stock stock attractive at the current price?
The data as of Sep 24, 2026: price $1.13, calculated fair value $2.73 (+142%), Quality Score 38/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MGX calculated?
We run Metagenomi, Inc. Common Stock through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $2.73, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Metagenomi, Inc. Common Stock currently trades 142 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Metagenomi, Inc. (MGX)?
The closing price on Sep 23, 2026 was $1.13. Our model-based fair value is $2.73, about +142% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Metagenomi, Inc. Common Stock right now?
The large discount to fair value meets weak quality (38/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($1.80). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($1.80 to $3.41) leaves room in how you read the outcome.

Key figures of Metagenomi, Inc. Common Stock

How large is the market capitalisation of Metagenomi, Inc. (MGX)?
The market capitalisation of Metagenomi, Inc. Common Stock is $42.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Metagenomi, Inc. (MGX)?
The price-to-sales ratio of Metagenomi, Inc. Common Stock is 3.20 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Metagenomi, Inc. (MGX)?
Earnings per share at Metagenomi, Inc. Common Stock are $−2.46. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Metagenomi, Inc. (MGX)?
The return on equity (ROE) of Metagenomi, Inc. Common Stock is −60.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Metagenomi, Inc. (MGX)?
On an EBIT basis the return on assets of Metagenomi, Inc. Common Stock is −24.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Metagenomi, Inc. (MGX)?
The operating margin of Metagenomi, Inc. Common Stock is 11,196% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Metagenomi, Inc. (MGX)?
Revenue at Metagenomi, Inc. Common Stock is growing −69.8% versus a year earlier (3y avg +13.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Metagenomi, Inc. (MGX) generate?
The free cash flow of Metagenomi, Inc. Common Stock is −$89.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Metagenomi, Inc. (MGX) hold?
Metagenomi, Inc. Common Stock holds more cash than debt, $1.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Metagenomi, Inc. Common Stock in the live analysis

One click puts Metagenomi, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.